Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 3085140, 15 pages
Review Article

Cognitive Impact of Deep Brain Stimulation on Parkinson’s Disease Patients

1University of Texas Health Science Center, Houston, TX, USA
2Parkinson’s, Movement Disorders and Neurorestoration Program, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia
3Center for Neurological Restoration, Cleveland Clinic, Cleveland, OH, USA
4University of Florida, Gainesville, FL, USA

Correspondence should be addressed to Raja Mehanna; ude.cmt.htu@annahem.ajar

Received 21 February 2017; Revised 15 May 2017; Accepted 16 October 2017; Published 22 November 2017

Academic Editor: Carlo Colosimo

Copyright © 2017 Raja Mehanna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Subthalamic nucleus (STN) or globus pallidus interna (GPi) deep brain stimulation (DBS) is considered a robust therapeutic tool in the treatment of Parkinson’s disease (PD) patients, although it has been reported to potentially cause cognitive decline in some cases. We here provide an in-depth and critical review of the current literature regarding cognition after DBS in PD, summarizing the available data on the impact of STN and GPi DBS as monotherapies and also comparative data across these two therapies on 7 cognitive domains. We provide evidence that, in appropriately screened PD patients, worsening of one or more cognitive functions is rare and subtle after DBS, without negative impact on quality of life, and that there is very little data supporting that STN DBS has a worse cognitive outcome than GPi DBS.